Our CareConnectPSS® Case Managers can help you understand yourinsurance benefits, so you can get access to the treatment you need. Sanofi also offers copay assistance and charitable access programs for eligible patients.
The CareConnectPSS Co-Pay Program* helps eligible, US patients who are prescribed one of Sanofi's treatments pay for eligible, out-of-pocket, drug-related expenses, including co-pays, coinsurance, and deductibles.
The program is open to individuals who:
The program is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), or other federal or state programs (including any state prescription drug assistance programs).
The CareConnectPSS Co-Pay Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-pay benefits are not transferable. This program assists patients with their out-of-pocket drug costs for their prescribed Sanofi treatment only and does not cover or provide support for the cost of MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, premedications/other medications, Epipens, transportation or other related services. No claim for reimbursement of any out-of-pocket expense covered by the CareConnectPSS Co-Pay Program may be submitted to any third-party payer, where public or private. Sanofi reserves the right to make eligibility decisions, set program maximums, and rescind, revoke, or amend this program without notice.
Sanofi Charitable Access Program
This program was established in the US to provide Sanofi's therapies to eligible individuals who do not have health insurance or have inadequate coverage for treatment. It is considered a temporary solution until long-term coverage can be secured.
The Sanofi Charitable Access Program has been established in the United States through the Sanofi Charitable Foundation, Inc. The program is committed to providing Cerezyme to individuals who:
Qualified individuals with Gaucher disease type 1 whose physicians have recommended treatment with Cerezyme may be eligible for the Charitable Access Program. If a patient is ineligible for the program, their CareConnectPSS Case Manager will work with the patient and their health care providers to explore alternative coverage options.
To be considered for the program, patients will be asked to provide the following:
A CareConnectPSS Case Manager will coordinate with you to obtain the necessary documentation, including a signed waiver, and keep you updated on the status of your application. Applications are reviewed on a monthly basis and are kept confidential by the Sanofi Charitable Access Program.
Please note that the Sanofi Charitable Access Program is considered a temporary program. Patients and their families are expected to continue exploring alternative resources with the assistance of a CareConnectPSS Case Manager. These may include:
To learn more about the Sanofi Charitable Access Program or to
request an application form,
call 1‑800‑745‑4447, Option 3
The Sanofi Charitable Access Program may be discontinued at any time at the discretion of the Charitable Access Program Committee.
Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:
Hypersensitivity and Infusion-Associated Reactions: Serious allergic reactions (anaphylaxis) have been reported in patients treated with Cerezyme. Symptoms suggestive of an allergic reaction have been reported during or shortly after an infusion and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), rapid heart rate, and low blood pressure. Inform your doctor and seek medical care if you experience any of these symptoms. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.
Immune Responses: Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies.
Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting.
Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults.
Please see the Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Medical Information at 1-800-745-4447, Option 2.